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Abstract
Personalized Medicine (PM) is a new paradigm where physicians use all the available information
(clinical  history,  molecular  profile,  DNA, imaging etc.)  of  each patient  to tailor  the treatment to
his/her unique individual characteristics. One of the most evident physiological features of a person
is its biological sex [1]. However, this information is rarely used in clinical research and we know
little about  the role that  plays in determining many clinically-relevant  features such as disease
predisposition or sensitivity to different treatments. 
For  instance,  in  2009,  only  20%  of  biomedical  experiments  employing  animals  published  in
journals such Nature, Science or PLoS Biology, considered both sexes [2]. The 20% and the 10%
of the publications did only studied males or females separately [2]. The remaining 50% did not
even reported the sex of the animals which unexplicitly indicates that sexual dimorphism might be
deemed as irrelevant [2]. When the research focuses on cell cultures, something similar happens:
only 30% of articles reported the sex of the cells [3]. The panorama changes when the subject of
study  are  humans:  more  than  60%  of  the  scientific  experiments  contemplated  both  sexes
meanwhile the remaining 40% take mostly men as reference [2].
One of  the main reason for  these inequalities seems to be an economic issue.  For  example,
female  Wistar rats are 4 times more expensive compared to male ones [4]. This situation is not
only relegated to animals but also humans. In Biomedical Research, women are considered a
confounding  variable  as  well  as  more  expensive  due  to  their  fluctuating  hormone  levels  [5].
Besides, pregnant women or of childbearing potential are usually excluded [5]. Despite these facts,
a direct correlation exists between the number of GSA (Gender and Sex Analyses) and the number
of  female authors involved in such publications.  Evidence shows that independently of women
being the first or last author or more numerous among the group of authors, they are more likely to
perform GSA [6].
In general, the omission of GSA in Biomedical Research has regrettable repercussions. A good
exemplification of this is the case of the withdrawal of 10 drugs from the market in the late 90s in
USA. Of those, 7 provoked side effects on female population [4]. On the other hand,  although one
third of hip fractures caused by osteoporosis happens in elder men, the focus group when studying
it points to women as its appearance has been largely linked to menopause [4].
Diverse organizations such the European Commission or the National Institutes of Health (NIH) in
USA among others, have acknowledged the importance of this matter by establishing new policies
and goals within their scope of Biomedical research [5,7,8,9].
Although measures to increase GSA are being implemented, we are still far from understanding
the role of biological sex in PM. A critical step that will  bring us closer to this goal will  be the
inclusion of "biological sex" as a key variable in all future biomedical research. That way, we will be
able to tailor clinical treatments to benefit both sexes.
Cited Bibliography
1. Clayton JA, Collins FS. Policy: NIH to balance sex in cell and animal studies. Nature. 
2014;509(7500):282-3.
2. Beery AK, Zucker I. Sex bias in neuroscience and biomedical research. Neurosci Biobehav 
Rev. 2011;35(3):565-72.
3. Shah K, Mccormack CE, Bradbury NA. Do you know the sex of your cells?. Am J Physiol, 
Cell Physiol. 2014;306(1):C3-18.
4. Wald C, Wu C. Biomedical research. Of mice and women: the bias in animal models. 
Science. 2010;327(5973):1571-2.
5. Liu KA, Mager NA. Women's involvement in clinical trials: historical perspective and future 
implications. Pharm Pract (Granada). 2016;14(1):708.
6. Nielsen, M. W., Andersen, J. P., Schiebinger, L., & Schneider, J. W. (2017). One and a half 
million medical papers reveal a link between author gender and attention to gender and sex
analysis. Nature Human Behaviour, 1, 791-796.
7. National Institutes of Health (NIH). Consideration of sex as a biological variable in NIH-
funded research. 2015.
8. European Commission. Horizon 2020 Work Programme 2018-20120 (2018). 
9. Canadian Institutes of Health Research. Science is better with sex and gender (2018).
